CC BY 4.0 · TH Open 2021; 05(02): e134-e138
DOI: 10.1055/s-0041-1727121
Case Report

Treatment of a Critically Ill COVID-19 Patient with the Seraph 100 Microbind Affinity Filter

Anke Pape
1  Kuratorium für Dialyse und Nierentransplantation, Pelikanplatz, Hannover, Germany
2  Department of Nephrology, Angiology and Rheumatology, KRH Klinikum Siloah, Hannover, Germany
3  Department of Nephrology, University Hospital of Essen, University of Duisburg-Essen, Essen, Germany
,
4  Medical Clinic V Nephrology, Rheumatology, Blood Purification, Academic Teaching Hospital Braunschweig, Braunschweig, Germany
,
Tillman Krüger
1  Kuratorium für Dialyse und Nierentransplantation, Pelikanplatz, Hannover, Germany
2  Department of Nephrology, Angiology and Rheumatology, KRH Klinikum Siloah, Hannover, Germany
,
Thomas Fühner
5  Department of Respiratory and Critical Care Medicine, KRH Klinikum Siloah, Hannover, Germany
,
Reinhard Brunkhorst
1  Kuratorium für Dialyse und Nierentransplantation, Pelikanplatz, Hannover, Germany
2  Department of Nephrology, Angiology and Rheumatology, KRH Klinikum Siloah, Hannover, Germany
› Institutsangaben
Funding None.

Abstract

The coronavirus disease 2019 (COVID-19) pandemic has a serious impact on health and economics worldwide. Even though the majority of patients present with moderate and mild symptoms, yet a considerable portion of patients need to be treated in the intensive care unit. Aside from dexamethasone, there is no established pharmacological therapy. Moreover, some of the currently tested drugs are contraindicated for special patient populations like remdesivir for patients with severely impaired renal function. On this background, several extracorporeal treatments are currently explored concerning their potential to improve the clinical course and outcome of critically ill patients with COVID-19. Here, we report the use of the Seraph 100 Microbind Affinity filter, which is licensed in the European Union for the removal of pathogens. Authorization for emergency use in patients with COVID-19 admitted to the intensive care unit with confirmed or imminent respiratory failure was granted by the U.S. Food and Drug Administration on April 17, 2020.

A 53-year-old Caucasian male with a severe COVID-19 infection was treated with a Seraph Microbind Affinity filter hemoperfusion after clinical deterioration and commencement of mechanical ventilation. The 70-minute treatment at a blood flow of 200 mL/minute was well tolerated, and the patient was hemodynamically stable. The hemoperfusion reduced D-dimers dramatically.

This case report suggests that the use of Seraph 100 Microbind Affinity filter hemoperfusion might have positive effects on the clinical course of critically ill patients with COVID-19. However, future prospective collection of data ideally in randomized trials will have to confirm whether the use of Seraph 100 Microbind Affinity filter hemoperfusion is an option of the treatment for COVID-19.



Publikationsverlauf

Eingereicht: 20. September 2020

Angenommen: 21. Januar 2021

Publikationsdatum:
14. April 2021 (online)

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany